Company: BSX
Filing Date: 2025-02-18
Form Type: 10-K
Source: 0000885725-25-000011
Chunk: 84

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-18
Form: 10-K
Item: Item 7
Chunk 84
---
 $— $(8)$1,853 $1.25 Non-GAAP adjustments:Amortization expense856 113 743 — 9 734 0.49 Goodwill and other intangible asset impairment charges386 48 339 — — 339 0.23 Acquisition/divestiture-related net charges (credits)403 28 375 — — 375 0.25 Restructuring and restructuring-related net charges (credits)229 30 199 — — 199 0.13 Litigation-related net charges (credits)— 0 (0)— — (0)(0.00)Investment portfolio net losses (gains) and impairments20 1 19 — — 19 0.01 European Union (EU) Medical device regulation (MDR) implementation costs52 7 45 — — 45 0.03 Deferred tax expenses (benefits)— (165)165 — — 165 0.11 Discrete tax items— 4 (4)— — (4)(0.00)Adjusted$4,229 $502 $3,726 $— $1 $3,725 $2.51 

 Year Ended December 31, 2023(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Preferred Stock DividendsNet Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per Share(4)Reported$1,985 $393 $1,592 $(23)$(1)$1,570 $1.07 Non-GAAP adjustments:Amortization expense828 115 713 — 4 709 0.48 Goodwill and other intangible asset impairment charges58 4 54 — — 54 0.04 Acquisition/divestiture-related net charges (credits)373 21 352 — — 352 0.24 Restructuring and restructuring-related net charges (credits)185 29 156 — — 156 0.11 Litigation-related net charges (credits)(111)(23)(88)— — (88)(0.06)Invest